Skip to main content

Table 2 Primary and secondary outcomes for HIV-positive patients with CMVR treated at MTY Clinic, Myanmar, 2013–2017

From: Treating HIV-associated cytomegalovirus retinitis with oral valganciclovir and intra-ocular ganciclovir by primary HIV clinicians in southern Myanmar: a retrospective analysis of routinely collected data

 

Total (N = 53)

Local treatment (N = 21)

Systemic treatment (N = 32)

P value

Median (IQR) duration of treatment, daysa

98 (55–172)

63 (21–92)

133 (80–195)

< 0.01

Outcome, N (%)

   

0.665

 Improvement

7 (13)

2 (10)

5 (16)

 

 Stable

30 (57)

11 (52)

19 (59)

 

 Deterioration

3 (6)

2 (10)

1 (3.1)

 

 Deceased

9 (17)

5 (24)

4 (12.5)

 

 Lost to follow up

1 (1.9)

0 (0)

1 (3.1)

 

 Unknown

3 (5.7)

1 (5)

2 (6.3)

 

Worsening anaemia, N (%)

20 (38)

N/A

20 (63)

 

CD4 count ≥100 cells/μL, N (%)b

 3 months

19 (36)

9 (43)

10 (31)

0.170

 6 months

29 (55)

11 (52)

18 (56)

1

 12 months

32 (60)

9 (43)

23 (72)

0.571

  1. CMVR Cytomegalovirus retinitis; IQR Interquartile range; MTY Mittar Yeik; N/A Not applicable.
  2. a Excludes one patient treated with valganciclovir who was lost to follow-up.
  3. b Excludes nine patients who died (no CD4 count from follow-up).